VTU Technology is now VALIDOGEN
PRESS RELEASE | VALIDOGEN GmbH
OCTOBER 22, 2018
Change of Company Name: VTU Technology is now VALIDOGEN
UNLOCK PICHIA – A technology from VALIDOGEN
Raaba-Grambach, Austria: – VTU Technology GmbH, a leading, globally acting Austrian biotech contract research company developing microbial strains and processes for the production of recombinant proteins, announced today the change of its company name to VALIDOGEN GmbH following a reorganization of VTU Holding GmbH.
Founded in 2008, VTU Technology has become a recognized player in the field of Pichia pastoris based protein production and will now continue its business as VALIDOGEN, a private company and independent subsidiary of KonValue Group. VALIDOGEN will continue to be a leading partner for the development of microbial protein production strains and processes“, said Dr. Michael Koncar, founder and CEO of VALIDOGEN and KonValue Group.
UNLOCK PICHIA – a technology from VALIDOGEN
In connection with the company’s name change, VALIDOGEN introduces UNLOCK PICHIA as a label for its established, exclusive Pichia protein production technology. UNLOCK PICHIA is known as the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein production.
The company has been continuously working on the optimization and expansion of its Pichia toolbox, which is unmatched in terms of genetic diversity. UNLOCK PICHIA addresses challenges all the way from transcription and translation to translocation, protein folding and secretion and facilitates the expression of more complex proteins thus maximizing yields without compromising product quality.
About VALIDOGEN GmbH
VALIDOGEN, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein production known as UNLOCK PICHIA. VALIDOGEN develops high performance expression strains and economically viable protein production processes for the manufacture of biopharmaceuticals, enzymes and various other recombinant proteins and provides tailor- made solutions for customers from different industry sectors – such as pharma, diagnostics, food & feed, chemical, agro and other industries. VALIDOGEN will be a private company and independent subsidiary of KonValue Group.
Dr. Thomas Purkarthofer, Head of Business Development, VALIDOGEN GmbH
Tel.: +43 316 4009 4017